Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial
Objective: Evaluate the long-term effect of ADS-5102 on OFF time among Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Background: ADS-5102, the only drug FDA-approved…Andrograholide protect microglial activation via inhibiting mitochondrial ROS generation and NLRP3 inflammasome activation in in-vitro and in-vivo model of Parkinson’s disease
Objective: Parkinson's disease (PD) is a distressing neurodegenerative disorder effecting nearly 2-3% of the total population greater than 65 years old . Several mechanisms have…The add-on effect of Lactobacillus plantarum PS128 in patients with Parkinson’s disease: A pilot study
Objective: We aimed to investigate the add-on effect of Lactobacillus plantarum PS128 (PS128) in patients with Parkinson’s disease (PD). Background: PS128 is a specific probiotic…Claims Data Analysis of Parkinson’s Disease Medication Utilization
Objective: Characterize prominent medication utilization patterns among patients with Parkinson’s disease (PD). Background: Multiple classes of medications, as monotherapy or polytherapy, are prescribed to treat…Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease
Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…Opicapone and entacapone as add-on therapy to the treatment of infusions of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease
Objective: To study the effect of COMT inhibitors (opicapone and entacapone) in Parkinson's disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) and an insufficient control of…Efficacy and Safety of High Doses of Safinamide in Advanced Parkinson’s Disease Patients in a Real-World Experience
Objective: To evaluate in a real-world experience high doses of safinamide in patients with fluctuating Parkinson's disease (PD). Background: Standard doses of safinamide (50-100 mg)…Inhaled levodopa (LD) as a treatment for Parkinson’s disease (PD) patients in an emergency setting
Objective: To report on use of CVT-301 (inhaled LD) to treat PD patients with complicated OFF period symptoms who present to the emergency department (ED).…Topographical subtypes of multiple system atrophy: MRI and PET studies
Objective: To investigate the MSA subtypes based on the topography of MSA lesions, employing MRI, PET with [18F]FP-CIT and [18F]FDG PET. Background: Based on the…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.